Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.

MLA

Salles, Gilles, et al. “Single-Agent Ibrutinib in RESONATE-2™ and RESONATE™ versus Treatments in the Real-World PHEDRA Databases for Patients with Chronic Lymphocytic Leukemia.” Annals of Hematology, vol. 98, no. 12, Dec. 2019, pp. 2749–60. EBSCOhost, https://doi.org/10.1007/s00277-019-03830-8.

APA

Salles, G., Bachy, E., Smolej, L., Simkovic, M., Baseggio, L., Panovska, A., Besson, H., Healy, N., Garside, J., Iraqi, W., Diels, J., Pick-Lauer, C., Spacek, M., Urbanova, R., Lysak, D., Hermans, R., Lundbom, J., Callet-Bauchu, E., & Doubek, M. (2019). Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. Annals of Hematology, 98(12), 2749–2760. https://doi.org/10.1007/s00277-019-03830-8

Chicago

Salles, Gilles, Emmanuel Bachy, Lukas Smolej, Martin Simkovic, Lucile Baseggio, Anna Panovska, Hervé Besson, et al. 2019. “Single-Agent Ibrutinib in RESONATE-2™ and RESONATE™ versus Treatments in the Real-World PHEDRA Databases for Patients with Chronic Lymphocytic Leukemia.” Annals of Hematology 98 (12): 2749–60. doi:10.1007/s00277-019-03830-8.